Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Jun 8, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether following the Autoimmune Protocol (AIP) diet can help reduce protein levels in the urine of individuals with IgA Nephropathy (IgAN), a kidney disease that can progress to kidney failure. The AIP diet eliminates certain foods that may cause inflammation, such as dairy, grains, and sugar, for 8 weeks, after which these foods are gradually reintroduced over a period of 4 months. The study aims to enroll 30 adults aged 18 to 65 who have been diagnosed with IgAN and are experiencing protein in their urine. Participants will follow the diet for 6 months, keep a food diary, and monitor their urine protein levels daily at home, while receiving monthly check-ups from a healthcare professional.
To be eligible for this trial, participants must be between the ages of 18 and 65, have a confirmed diagnosis of IgAN with a specific level of protein in their urine, and be stable on certain medications for at least a month. They should also not have other serious health conditions that could affect their participation. By the end of the study, the researchers hope to see a reduction in urine protein of 20% or more, which could help slow down the disease progression and lessen the need for treatments like dialysis. This trial is an opportunity for eligible individuals to potentially improve their kidney health through dietary changes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18-65
- • Diagnosed with IgA Nephropathy (IgAN)
- • Active disease with urine protein/creatinine ratio ≥ 1
- • Stable ARB or ACE inhibitor for at least 1 month prior
- • GFR \> 30
- • Not on Budesonide 1 month prior or during study
- Exclusion Criteria:
- • Inability to comply with dietary or follow-up requirements
- • Participation in other interventional studies
- • Significant comorbidities interfering with study participation -
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manhattan Beach, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported